Pay in 4 interest-free payments of $30.00 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
OG-L002 suppressed primary lytic infection of HSV in vivo in a mouse model
Smiles: CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C
InChi: InChI=1S/C18H24O/c1-5-18(4
The drug was developed by Valeant Pharmaceuticals and GlaxoSmithKline
1 µM for Narciclasine
LP-261 - CAS# 915412-67-8 Size:2mg solid OG-L002 suppressed primary lytic infectionLP 261 is a novel tubulin targeting anticancer agent that binds at the colchicine site on tubulin, inducing G2 M arrest. Screening in the NCI60 cancer cell lines resulted in a mean GI50 of approximately 100 nM. LP 261 is a very potent inhibitor of angiogenesis, preventing microvessel outgrowth in the rat aortic ring assay and HUVEC cell proliferation at nanomolar concentrations. Complete inhibition of tumor growth was achieved in the PC3 xenograft
US$ 500.00
US$ 2000.00
US$ 1800.00
US$ 400.00
US$ 1100.00
US$ 1200.00
US$ 812.50
US$ 900.00
US$ 1200.00
US$ 400.00
US$ 1375.00
US$ 1200.00
US$ 600.00
US$ 1100.00
US$ 650.00
US$ 400.00
US$ 900.00